- Finalization of agreement with Dutch distribution partner
allows access into another key European market
- KM Innovations is a well-established partner with deep
existing relationships in neurosurgical space
STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- IRRAS AB, a
commercial-stage medical technology company with a comprehensive
portfolio of innovative products for neurocritical care, today
announced an exclusive distribution agreement with KM Innovations
BV, a leading distributor of world-class neurosurgical medical
devices and technologies in The
Netherlands.
"We are pleased to partner with KM Innovations to expand the
commercial availability of our IRRAflow® product line to
physicians and patients throughout the
Netherlands," said Coenraad
Tamse, Vice President of International Sales for IRRAS. "As
we expand the launch of our products throughout Europe, this partnership strategically expands
our commercial capabilities with a large and established
distributor with 35 years of experience supplying cutting-edge
neurosurgical technologies."
Sanne Krijnen, Managing Director
of KM Innovations Medical, commented, "We are excited to add
IRRAflow to our product portfolio as it allows us to bring
our customers a next generation solution for the treatment of
intracranial bleeding and hemorrhagic stroke. This exclusive
distribution agreement expands our proven record of success in
bringing safe and effective, leading-edge medical technologies to
our Dutch clients, and we look forward to our partnership with
IRRAS."
About KM Innovations
Krijnen Medical Innovations BV has been a distributor of
innovative surgical technologies since 1985. With a head
office in Waardenburg, the
Netherlands, Krijnen Medical serves customers in
the Netherlands, Belgium, France, and Luxembourg with dedicated sales professionals
to support its general, cardio, vascular, thoracic, and
neurosurgical product lines.
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP
Monitoring product lines to hospitals worldwide through its direct
sales organization in the United
States and select European countries as well as an
international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
USA
Kleanthis G. Xanthopoulos, Ph.D.
CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com
The information was released for public disclosure, through
the agency of the contact person above, on November 26, 2020 at 08:00 (CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-announces-expansion-of-irraflow-launch-to-the-netherlands,c3243786